enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Papillary urothelial neoplasm of low malignant potential

   en.wikipedia.org/wiki/Papillary_urothelial...

   They cannot be reliably differentiated from low grade papillary urothelial carcinomas using cytology, [1] and their diagnosis (vis-a-vis low grade papillary urothelial carcinoma) has a poor inter-rater reliability. [2] Pathologic grading and staging tumors are: graded by the degree of cellular atypia (G1->G3), and staged: [citation needed ...

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Severe bladder tumors often shed cells into the urine; these can be detected by urine cytology, where cells are collected from a urine sample, and viewed under a microscope. [6] [7] Cytology can detect around two thirds of high-grade tumors, but detects just 1 in 8 low-grade tumors. [8]

4. Transitional cell carcinoma - Wikipedia

   en.wikipedia.org/wiki/Transitional_cell_carcinoma

   It accounts for 95% of bladder cancer cases and bladder cancer is in the top 10 most common malignancy disease in the world and is associated with approximately 200,000 deaths per year in the US. [2] [3] It is the second most common type of kidney cancer, but accounts for only five to 10 percent of all primary renal malignant tumors. [4]

5. FDA approves bladder cancer treatment by Culver City company

   www.aol.com/news/fda-approves-bladder-cancer...

   For premium support please call: 800-290-4726 more ways to reach us

6. Invasive urothelial carcinoma - Wikipedia

   en.wikipedia.org/wiki/Invasive_urothelial_carcinoma

   It is a type of cancer that develops in the urinary system: the kidney, urinary bladder, and accessory organs. Transitional cell carcinoma is the most common type of bladder cancer and cancer of the ureter, urethra, renal pelvis, the ureters, the bladder, and parts of the urethra and urachus.

7. Nadofaragene firadenovec - Wikipedia

   en.wikipedia.org/wiki/Nadofaragene_firadenovec

   The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.